

Product

CPR Invest - MedTech - A CZKH - Acc

A Sub-Fund of CPR Invest

LU2183822316 - Currency: CZK

This Sub-Fund is authorised in Luxembourg.

Management Company: CPR Asset Management (hereafter: "we"), a member of the Amundi Group of companies, is authorised in Luxembourg and regulated by the Commission de Surveillance du Secteur Financier (CSSF).

CSSF responsible for supervising CPR Asset Management in relation to this Key Information Document.

For more information, please refer to www.cpr-am.com or call +33 53157000.

This document was published on 23/12/2022.

KEY
INFORMATION
DOCUMENT

What is this product?

Type: Shares of a Sub-Fund of CPR Invest, a SICAV.

Term: The term of the Sub-Fund is unlimited. The Management Company may terminate the fund by liquidation or merger with another fund in accordance with legal requirements.

Objectives: The investment objective is to outperform global equity markets over a long-term period (minimum of five years) by investing in international equities of companies involved in the medical technology ecosystem, while integrating Environmental, Social and Governance (E, S, and G - or, when taken together, ESG) criteria in the investment process.

To achieve this, the Compartment aims to select equities of companies with the best financial perspectives within a universe of companies involved in the medical technology ecosystem through sector such as diagnostics, surgery, medical monitoring, disease prevention, treatment. The Management Company integrates a sustainable approach by excluding companies based on the following :

- worst overall ESG ratings;
- worst ratings on E, S and G specific criteria deemed relevant for the medical technology ecosystem;
- high ESG controversies;

The best-in-class approach does not exclude any sector of activity in principle. All economic sectors are therefore represented in this approach and the Compartment may therefore be exposed to some controversial sectors.

The Compartment equity exposure will be between 75% and 120% of its assets.

The Compartment is invested for at least 75% of its assets in equity and equity equivalent securities of any country without constraints of capitalisation. Among this proportion of 75% of its assets, the Compartment

may invest in China A shares via Stock Connect within a maximum of 25% of its assets.

Derivative instruments will be used for hedging, arbitrage, exposure purposes and/or efficient portfolio management.

The Compartment is actively managed. The Compartment may use a Benchmark a posteriori as an indicator for assessing the Compartment's performance and, as regards the performance fee benchmark used by relevant share classes, for calculating the performance fees. There are no constraints relative to any such Benchmark restraining portfolio construction.

The Compartment is a financial product that promotes ESG characteristics pursuant to Article 8 of the Disclosure Regulation.

Intended Retail Investor: This product is intended for investors, with a basic knowledge of and no or limited experience of investing in funds seeking to increase the value of their investment over the recommended holding period and who are prepared to take on a high level of risk to their original capital.

Redemption and Dealing: Shares may be sold (redeemed) as stated in the prospectus at the respective dealing price (net asset value). Further details are provided in the CPR Invest prospectus.

Distribution Policy: As this is a non-distributing share class, investment income is reinvested.

More Information: You may get further information about the Sub-Fund, including the prospectus, and financial reports which are available at and free of charge on request from: CPR Asset Management at 91-93, boulevard Pasteur – CS 61595 – 75730 Paris Cedex 15.

The Net Asset Value of the Sub-Fund is available on www.cpr-am.com.

Depository: CACEIS Bank, Luxembourg Branch.

What are the risks and what could I get in return?

RISK INDICATOR



Lower Risk

Higher Risk



The risk indicator assumes you keep the product for Supérieur à 5 ans.

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movement in the markets or because we are not able to pay you.

PERFORMANCE SCENARIOS

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the Sub-Fund over the last Supérieur à 5 ans. Markets could develop very differently in the future. The stress scenario shows what you might get back in extreme market circumstances.

What you get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

Recommended holding period : 5 year(s) Investment CZK 10,000			
Scenarios		If you exit after	
		1 year	5 year(s)
Minimum	There is no minimum guaranteed return. You could lose some or all of your investment.		
Stress Scenario	What you might get back after costs	CZK4,280	CZK2,760
	Average return each year	-57.2%	-22.7%
Unfavourable Scenario	What you might get back after costs	CZK6,530	CZK7,050
	Average return each year	-34.7%	-6.8%
Moderate Scenario	What you might get back after costs	CZK11,010	CZK20,170
	Average return each year	10.1%	15.1%
Favourable Scenario	What you might get back after costs	CZK14,670	CZK25,570
	Average return each year	46.7%	20.7%

We have classified this product as 4 out of 7, which is a medium risk class. This rates the potential losses from future performance at a medium level, and poor market conditions could impact our capacity to pay you.

Additional risks: Market liquidity risk could amplify the variation of product performances.

This product does not include any protection from future market performance so you could lose some or all of your investment.

Beside the risks included in the risk indicator, other risks may affect the Sub-Fund's performance. Please refer to the CPR Invest prospectus.

The figures shown include all the costs of the product itself, but may or may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

This type of scenario occurred for an investment using a suitable proxy.

What happens if CPR Asset Management is unable to pay out?

A separate pool of assets is invested and maintained for each Sub-Fund of CPR Invest. The assets and liabilities of the Sub-Fund are segregated from those of other sub-funds as well as from those of the Management Company, and

there is no cross-liability among any of them. The Sub-Fund would not be liable if the Management Company or any delegated service provider were to fail or default.

What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, and how long you hold the product. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- In the first year you would get back the amount that you invested (0 % annual return). For the other holding periods we have assumed the product performs as shown in the moderate scenario.
- CZK 10,000 is invested.

COSTS OVER TIME

Scenarios	Investment CZK 10,000	
	1 year	If you exit after Supérieur à 5 ans*
Total Costs	CZK692	CZK2,599
Annual Cost Impact**	7.0%	3.5%

* Recommended holding period.

** This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 18.61% before costs and 15.06% after costs.

These figures include the maximum distribution fee that the person selling you the product may charge (5.00% of amount invested / 525 CZK). This person will inform you of the actual distribution fee.

If you are invested in this product as part of an insurance contract, the costs shown do not include additional costs that you could potentially bear.

COMPOSITION OF COSTS

	One-off costs upon entry or exit	If you exit after 1 year
Entry costs	A fixed cost of 25 CZK	Up to 525 CZK
Exit costs	0.00 of your investment before it is paid out to you.	23.6875 CZK
Ongoing costs taken each year		
Management fees and other administrative or operating costs	1.91% of the value of your investment per year. This is an estimate based on actual costs over the last year.	181 CZK
Transaction costs	0.12% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	11 CZK
Incidental costs taken under specific conditions		
Performance fees	15.00% annual outperformance of the reference asset 15% of the performance realized by the Compartment relevant Share Class above the Reference Asset during a one year period. Reference Value :MSCI World Health Care Equipment and Supplies 10/40 Index NR in CZK cross hedged USD to CZK. The calculation applies on each Net Asset Value calculation date in accordance with the terms described in the prospectus. Past underperformances over the last 5 years should be clawed back before any new accrual of performance fee. The actual amount will vary depending on how well your investment performs. The aggregated cost estimation above includes the average over the last 5 years.	0 CZK

How long should I hold it and can I take money out early?

Recommended holding period: Supérieur à 5 ans is based on our assessment of the risk and reward characteristics and costs of the Sub-Fund.

This product is designed for medium-term investment; you should be prepared to stay invested for at least 5 years. You can redeem your investment at any time, or hold the investment longer.

Order Schedule: Orders to buy and/or sell (redeem) shares received and accepted by 14:00 on any Luxembourg business day are ordinarily processed on the same day (using the valuation of that day).

You may exchange shares of the Sub-Fund for shares of other sub-funds of CPR Invest in accordance with the CPR Invest prospectus.

How can I complain?

If you have any complaints, you may:

- Call our complaints hotline on +331 53 15 70 00
- Mail CPR Asset Management at 91-93 boulevard Pasteur, 75015 Paris, France
- E-mail to client.servicing@cpr-am.com

In the case of a complaint you must clearly indicate your contact details (name, address, phone number or email address) and provide a brief explanation of your complaint. More information is available on our website www.cpr-am.com.

If you have a complaint about the person that advised you about this product, or who sold it to you, they will tell you where to complain.

Other Relevant Information

You may find the prospectus, statutes, key investor documents, notices to investors, financial reports, and further information documents relating to the Sub-Fund including various published policies of the Sub-Fund on our website www.cpr-am.com. You may also request a copy of such documents at the registered office of the Management Company.

Past performance: You can download the past performance of the Sub-Fund over the last 5 years at www.cpr-am.com.

Performance scenarios: You can find previous performance scenarios updated on a monthly basis at www.cpr-am.com.

The data in this KID is as of 23/12/2022

Informace o rizikovosti a nákladovosti investičního produktu

V tomto dokumentu nalezne investor informace týkající se hodnocení rizika a výnosu investičního produktu a dále souhrnný odhad nákladů a poplatků souvisejících se správou produktu a pořízením a ukončením investice. Struktura uveřejněných informací vychází ze směrnice o trzích a finančních nástrojích (MIFID II).

1 Hodnocení rizika a výnosu

Hodnocení rizika a výnosu investičního produktu je prezentováno prostřednictvím syntetického ukazatele rizika a výnosu (SRRI).

Hodnota ukazatele vychází z historických dat a nemusí být spolehlivým vodítkem při pohledu do budoucnosti. Hodnota ukazatele se v průběhu času může změnit.

Název produktu (ISIN)	Doporučený investiční horizont (v letech)	Ukazatel rizika a výnosu (SRRI)
CPR Invest - MedTech A CZK H - Acc LU2183822316	5	6

Nižší riziko,
nižší
potenciální
výnos



Vyšší
riziko,
vyšší
potenciální
výnos

Nejnižší kategorie rizika neznamená, že investice je neriziková. (1 = Nejnižší riziko – obvykle nejnižší výnos / 7 = Nejvyšší riziko – obvykle nejvyšší výnos).

2 Souhrnný odhad nákladů a poplatků souvisejících se správou produktu a pořízením a ukončením investice.

Informace o nákladech a poplatcích jsou rozkryty, aby zákazník porozuměl celkovým nákladům a jejich možnému souhrnnému dopadu na návratnost investice. Struktura uveřejněných informací vychází ze směrnice o trzích a finančních nástrojích (MIFID II). Celkový dopad nákladů na investici klienta je zpravidla nižší.

CPR Invest - MedTech A CZK H - Acc	Odhad ročních nákladů při předpokládané investici 10 000 Kč			
	v %	v Kč		
Jednorázové náklady	Vstupní poplatek (nejvyšší možná částka, která může být účtována distributorem před uskutečněním investice)	3.00%	Kč	300.00
	Výstupní poplatek (nejvyšší možná částka, která může být účtována distributorem před uskutečněním investice)		Kč	-
Průběžné náklady	Náklady produktu (počítáno dle MIFID II ex ante, jiné než v KID)**	1.77%	Kč	176.50
	Z toho manažerský poplatek	1.50%	Kč	150.00
	Transakční náklady (průměrné náklady na nákup a prodej aktiv do fondu)	0.24%	Kč	-
	Výkonnostní poplatek	0.00%	Kč	-
Pobídka distributorovi hrazená z jednorázových nákladů		3.00%	Kč	300.00
Pobídka distributorovi hrazená z průběžných nákladů		1.05%	Kč	105.00
Celkové náklady za držení produktu během prvního roku investice		5.00%	Kč	476.50
Průměrné roční náklady za doporučený investiční horizont (p.a.)		2.60%	Kč	260.29

Reálný dopad nákladů na výkonnost konkrétní investice může být nižší. Zobrazené jednorázové náklady uvádějí maxima, které mohou být účtovány

* Případný výstupní poplatek se řídí platným ceníkem.

** Náklady produktu představují Poplatky za vedení a jiné správní nebo provozní náklady. Ve Statutu může být tento údaj označen pojmem Celková nákladovost.